Despite this, clinical benefit of targeting CD19 has been established leading to current approval of four CD19 targeting CAR T-cell therapies; tisagenlecleucel, axicabtagene ciloleucel, Lisocabtagene maraleucel and recently brexucabtagene autoleucel for different subtypes of B-cell lymphoma (Table 1). The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.